The price of Atossa Therapeutics Inc (NASDAQ:ATOS) shares last traded on Wall Street fell -10.95% to $1.87.
ATOS stock price is now 55.78% away from the 50-day moving average and 98.19% away from the 200-day moving average. The market capitalization of the company currently stands at $234.31M.
With the price target of $2, Maxim Group recently initiated with Buy rating for Atossa Therapeutics Inc (NASDAQ: ATOS).
In other news, WEAVER GREGORY L, Former EVP, CFO, & Director sold 50,000 shares of the company’s stock on Nov 15 ’23. The stock was sold for $32,500 at an average price of $0.65. Upon completion of the transaction, the Former EVP, CFO, & Director now directly owns 55 shares in the company, valued at $102.85. A total of 0.02% of the company’s stock is owned by insiders.
During the past 12 months, Atossa Therapeutics Inc has had a low of $0.59 and a high of $2.27. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 17.61, and a quick ratio of 17.61. The fifty day moving average price for ATOS is $1.2220 and a two-hundred day moving average price translates $0.9482 for the stock.
The latest earnings results from Atossa Therapeutics Inc (NASDAQ: ATOS) was released for Sep, 2023.
Atossa Therapeutics Inc(ATOS) Company Profile
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company’s lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
